文献速递血栓与止血

抗PF4抗体比抗肝素/PF4抗体更快更强触发血小板促凝血反应

Anti-PF4 antibodies trigger a faster and stronger platelet procoagulant response than anti-heparin/PF4 antibodies.
PubMed 文献 · Blood Adv · 2026-01-01

本研究比较抗PF4与抗肝素/PF4 IgG的内在促血栓特性,使用单克隆抗体1E12和5B9及微流控全血血栓模型。结果显示抗PF4更易诱导富含纤维蛋白的血小板-白细胞聚集体,更强增强凝血酶生成,并更快更强激活血小板及产生促凝血血小板和微囊泡,可能解释VITT及VITT样综合征的严重性。

要点

  • 抗PF4抗体比抗肝素/PF4抗体更易诱导全血中富含纤维蛋白的血小板-白细胞聚集体形成。
  • 抗PF4抗体1E12而非5B9能强效增强血浆凝血酶生成,且依赖血小板及凝血因子V和XI。
  • 抗PF4抗体更快更强激活血小板,更易诱导促凝血血小板(CD62P+/磷脂酰丝氨酸+)和促凝血微囊泡。

核心结论

  • 抗PF4抗体比抗肝素/PF4抗体触发更快更强的血小板激活和促凝血活性,可能贡献VITT及VITT样综合征的严重性。

研究设计与样本

  • 使用单克隆IgG1抗体1E12(抗PF4)和5B9(抗肝素/PF4),在微流控全血血栓模型、血浆凝血酶生成实验、血清素释放试验及人VITT和HIT样本中比较。

主要发现

  • 1E12在微流控全血模型中比5B9更易诱导富含纤维蛋白的血小板-白细胞聚集体形成。
  • 1E12强效增强血浆凝血酶生成,而5B9无此作用,且该效应仅在有血小板及凝血因子V和XI时发生。
  • 1E12比5B9更快更强激活血小板(血清素释放试验),并在人VITT和HIT样本中确认。
  • 1E12比5B9更易在富血小板血浆中诱导促凝血血小板(CD62P+/磷脂酰丝氨酸+),并在全血和富血小板血浆中产生促凝血微囊泡。

临床怎么用

  • 抗PF4抗体相关综合征(如VITT)的血栓严重性可能与其直接增强血小板促凝血活性有关,提示需关注抗体特异性对临床表型的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine-induced immune thrombocytopenia and thrombosis (VITT) and VITT-like syndromes are emerging causes of severe thrombocytopenia and thrombosis associated with immunoglobulin G (IgG) antibodies targeting platelet factor 4 (PF4). These syndromes are characterized by more frequent and severe thrombosis than heparin-induced thrombocytopenia (HIT), which is typically caused by antibodies targeting heparin-modified PF4 (anti-PF4/H). In this study, we compared the intrinsic prothrombotic properties of IgG anti-PF4 and anti-PF4/H to identify mechanisms that may contribute to the severity of VITT and VITT-like syndromes. Using the monoclonal IgG1 antibodies 1E12 (anti-PF4) and 5B9 (anti-PF4/H), we showed that IgG anti-PF4 exhibited an increased propensity to induce the formation of fibrin-rich platelet-leukocytes aggregates in a microfluidic model of whole-blood (WB) thrombosis. This phenomenon was related to a strong potentiation of thrombin generation in plasma by 1E12, but not by 5B9, and occurred only in the presence of platelets and coagulation factors V and XI. We also demonstrated a substantially faster and stronger ability of 1E12, compared with 5B9, to activate platelets using the serotonin release assay and confirmed these findings using human VITT and HIT samples. Furthermore, 1E12 was more likely than 5B9 to induce procoagulant platelets (CD62P+/phosphatidylserine+) in platelet-rich plasma (PRP) and to produce procoagulant microvesicles in WB and PRP. In conclusion, platelets are activated faster and exhibit more procoagulant activity in response to anti-PF4 than anti-PF4/H, which may contribute to the severity of VITT and VITT-like syndromes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Augros J, Rollin J, Benzakine J, et al. Anti-PF4 antibodies trigger a faster and stronger platelet procoagulant response than anti-heparin/PF4 antibodies. Blood Adv. 2026. PMID: 42685671. doi:10.1182/bloodadvances.2026020237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。